Screen and identify potentially thousands of hit monoclonal antibodies using up to 80,000 NanoPen® chambers per workflow.
Next generation sequencing for barcoded BCR sequences facilitates quick, high-throughput sequence recovery.
Bioinformatics determine sequence diversity and developability. Once threshold plasma titers are reached, hit sequences are returned in just six to twenty days!
Save time and money with an end-to-end workflow that quickly identifies relevant antibodies and provides a seamless path to developing humanized antibodies – in a six-month timeframe or less.
In addition to deploying the Beacon system to identify and select cells of interest, Curia accelerates “First-to-Human” workflows with everything you need to successfully bring a new drug to the clinic, including:
At Curia, we see every partnership as an opportunity to make an impact together. You can count on our dedicated team to work closely with you from beginning to end, ensuring you receive the communication, support and expertise you need to see your project successfully through to completion.
Whether you’re a small startup with a big idea or an established provider seeking additional production capacity, we can help you get started.